Differences
This shows you the differences between two versions of the page.
Next revision | Previous revisionBoth sides next revision |
virginia_benassi [2022/09/14 00:34] liam created | virginia_benassi [2022/09/14 00:40] (current) liam [History] |
---|
| |
**Virginia Benassi** is the Technical Officer for the [[World Health Organization]]'s R&D Blueprint.((//Request for Proposal (R4P) Evaluation of Supportive Care for Epidemics.// (2019, October 3). Wellcome Trust. https://web.archive.org/web/20220913223156/https://wellcome.org/sites/default/files/wellcome-rfp-2019-evaluation-supportive-care-epidemics.pdf)) | **Virginia Benassi** is the Technical Officer for the [[World Health Organization]]'s R&D Blueprint.((//Request for Proposal (R4P) Evaluation of Supportive Care for Epidemics.// (2019, October 3). Wellcome Trust. https://web.archive.org/web/20220913223156/https://wellcome.org/sites/default/files/wellcome-rfp-2019-evaluation-supportive-care-epidemics.pdf)) |
| |
| ===== History ===== |
| |
| In October 2019, Benassi was listed as a member of the Epidemics Supportive Care Guidelines (ESCG) panel for [[Wellcome Trust]] in a Request for Proposal document.((//Request for Proposal (R4P) Evaluation of Supportive Care for Epidemics.// (2019, October 3). Wellcome Trust. https://web.archive.org/web/20220913223156/https://wellcome.org/sites/default/files/wellcome-rfp-2019-evaluation-supportive-care-epidemics.pdf)) It stated the following: |
| |
| "We are seeking a supplier to evaluate the availability and quality of current supportive care guidelines (SCGs) for high-risk or epidemic-prone pathogens, examine SCG development and implementation, and assess the value of supportive care to R&D for medical countermeasures and the outcome of an outbreak/ epidemic." |